Device Trial Radar · NCT05302050
A Cognitive Behavioral Digital Therapeutic InterventiON for Glycemic Control in Type 2 Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Oct 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
500
Actual
Start
Mar 7, 2022
Primary completion
Dec 1, 2025
Study completion Dec 1, 2025
Sponsor
- Lead sponsor
- Better TherapeuticsNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Massachusetts General Hospital
- First posted
- Mar 31, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Randomized, controlled, pragmatic trial with open-label extension evaluating BT-001, an investigational digital therapeutic intended to help patients with type 2 diabetes improve their glycemic control.
Conditions
- Diabetes Type 2
Interventions
BT-001Device
BT-001is a software application that delivers treatment to participants with type 2 diabetes, using behavioral therapy. BT-001 is accessed via the participants' smartphone. The behavioral intervention process involves: Identifying maladaptive thoughts based on misinformed core beliefs that lead to disease-promoting behaviors; replacing maladaptive core beliefs with adaptive ways of thinking; and providing collaborative construction of behavioral exercises to test core beliefs. Each week, BT-001 asks participants to complete a new lesson, along with one skill exercise. The lessons are expected to take between 10-20 minutes to complete. In addition to completing a lesson and skill, participants will be directed to report plant-based meals consumed and minutes of exercise completed and to measure their blood sugar daily.
Control Mobile ApplicationDevice
The app asks patients brief questions about their health but does not include any behavioral therapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1cTime frame: Baseline and Day 180
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mass General Brigham Hospital and Clinics
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.